Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

NCT00395434 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors

Interventions

DRUG: Combretastatin A4 Phosphate (CA4P)
DRUG: Bevacizumab (Avastin)

Sponsor

Mateon Therapeutics